A
Avalo Therapeutics, Inc. (AVTX)
NCM – Real vaqt narxi. Valyuta: USD
19.94
-0.31 (-1.53%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
19.94
-0.31 (-1.53%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Avalo Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Qo'shma Shtatlarda immun vositachiligidagi yallig'lanish kasalliklari uchun IL-1β asosidagi davolash usullarini ishlab chiqadi. Uning asosiy mahsuloti AVTX-009 ni o'z ichiga oladi, bu interleykin-1β ga bog'lanadigan insonlashtirilgan monoklonal antitanadir, u yallig'lanish kasalliklarini davolash uchun 2-bosqichli klinik sinovda. Kompaniya ilgari Cerecor Inc. nomi bilan tanilgan va 2021 yil avgust oyida Avalo Therapeutics, Inc. nomini o'zgartirgan. Avalo Therapeutics, Inc. 2011 yilda tashkil etilgan va shtab-kvartirasi Ueyn, Pensilvaniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Dino C. Miano Ph.D. | Senior Vice President of CMC & Technical Operations |
| Dr. Garry A. Neil M.D. | President, CEO & Director |
| Dr. Mittie Doyle FACR, M.D. | Chief Medical Officer |
| Dr. Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board |
| Mr. Christopher Ryan Sullivan CPA |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | tm2613717d1_8k.htm |
| 2026-04-28 | 8-K | avtx-20260426.htm |
| 2026-04-10 | DEFA14A | defa14acombined.htm |
| 2026-04-10 | DEF 14A | avtx-20260408.htm |
| 2026-04-10 | ARS | avtx10-k2025asxfiled_wrap.pdf |
| 2026-03-27 | 8-K | avtx-20260323.htm |
| 2026-03-23 | S-8 | tm268193d1_s8.htm |
| 2026-03-23 | 10-K | avtx-20251231.htm |
| 2026-01-12 | 8-K | avtx-20260112.htm |
| 2026-01-08 | S-3 | tm261721-1_s3.htm |
| CFO & Head of Investor relations |
| Mr. Paul C. Varki J.D., M.P.H | Chief Legal Officer |
| Mr. Taylor Boyd | Chief Business Officer |
| Ms. Ashley Ivanowicz | Senior Vice President of Human Resources |
| Ms. Jennifer Riley | Chief Strategy Officer |